9.
Net Loss Per Share
Basic
and diluted net loss per common share was calculated as follows (in thousands except shares and per share amounts):
Schedule of Computation
of Basic and Diluted Net Loss Per Share
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Three Months
Ended | | |
Six Months
Ended | |
| | |
June
30, | | |
June
30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Numerator: | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (2,895 | ) | |
$ | (2,389 | ) | |
$ | (5,315 | ) | |
$ | (3,465 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted average shares
used in computing net loss per share – basic and diluted | |
| 36,576,567 | | |
| 24,049,113 | | |
| 34,000,539 | | |
| 19,498,306 | |
| Net loss per share –
basic and diluted | |
$ | (0.08 | ) | |
$ | (0.10 | ) | |
$ | (0.16 | ) | |
$ | (0.18 | ) |
For
the three and six months ended June 30, 2025, and 2024, the Company had a net loss and as such, all outstanding shares of
potentially dilutive securities were excluded from the calculation of diluted net loss per share as the inclusion would be
anti-dilutive.
Potentially
dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows
(in common stock equivalent shares):
Schedule of Potentially
Anti Dilutive Securities
| | |
2025 | | |
2024 | |
| | |
As
of June 30, | |
| | |
2025 | | |
2024 | |
| Options to purchase common stock | |
| 936,657 | | |
| 632,154 | |
| Common stock warrants | |
| 19,714,006 | | |
| 12,569,789 | |
| Total | |
| 20,650,663 | | |
| 13,201,943 | |
|